1. Home
  2. BOXL vs GNPX Comparison

BOXL vs GNPX Comparison

Compare BOXL & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boxlight Corporation

BOXL

Boxlight Corporation

HOLD

Current Price

$5.66

Market Cap

3.1M

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$3.95

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOXL
GNPX
Founded
1985
2009
Country
United States
United States
Employees
N/A
13
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
3.2M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
BOXL
GNPX
Price
$5.66
$3.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.3M
131.5K
Earning Date
04-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,743,612.00
N/A
Revenue This Year
$2.70
N/A
Revenue Next Year
$5.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.37
N/A
52 Week Low
$0.50
$0.14
52 Week High
$10.15
$12.97

Technical Indicators

Market Signals
Indicator
BOXL
GNPX
Relative Strength Index (RSI) 54.94 45.44
Support Level $0.90 $0.73
Resistance Level $8.42 $5.24
Average True Range (ATR) 1.28 0.56
MACD 0.13 -0.26
Stochastic Oscillator 36.64 10.66

Price Performance

Historical Comparison
BOXL
GNPX

About BOXL Boxlight Corporation

Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: